[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Transmedics Group Inc (TMDX)

Transmedics Group Inc (TMDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

TransMedics Reports Tomorrow With Its Expansion Promises Still Ahead of Its Revenue Reality

TransMedics Group (TMDX) reports first-quarter 2026 earnings after market close on May 5, 2026, with Wall Street watching closely to see whether the organ transplant technology leader can sustain its remarkable growth trajectory or if the recent deceleration signals a more fundamental shift. The company has delivered four consecutive quarters of triple-digit earnings surprises, yet analysts are now projecting an 11% year-over-year decline in Q1 EPS—a stark reversal that raises questions about whether operational headwinds, competitive pressures, or simply tougher comparisons are weighing on near-term results.

TransMedics Group is a medical technology company pioneering the Organ Care System (OCS), a portable extracorporeal warm...

Fundamentals

See More
  • Market Capitalization, $K 3,352,367
  • Shares Outstanding, K 34,532
  • Annual Sales, $ 605,490 K
  • Annual Income, $ 190,290 K
  • EBIT $ 109 M
  • EBITDA $ 136 M
  • 60-Month Beta 2.07
  • Price/Sales 5.70
  • Price/Cash Flow 25.47
  • Price/Book 7.25

Options Overview Details

View History
  • Implied Volatility 82.81% (-0.16%)
  • Historical Volatility 52.88%
  • IV Percentile 83%
  • IV Rank 68.81%
  • IV High 100.33% on 07/17/25
  • IV Low 44.14% on 06/10/25
  • Expected Move (DTE 9) 12.31 (12.97%)
  • Put/Call Vol Ratio 0.53
  • Today's Volume 5,602
  • Volume Avg (30-Day) 2,146
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 36,910
  • Open Int (30-Day) 27,654
  • Expected Range 82.62 to 107.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.62
  • Number of Estimates 5
  • High Estimate $0.82
  • Low Estimate $0.55
  • Prior Year $0.70
  • Growth Rate Est. (year over year) -11.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
94.61 +0.34%
on 05/05/26
120.91 -21.49%
on 04/17/26
-5.76 (-5.73%)
since 04/02/26
3-Month
93.08 +1.99%
on 03/30/26
151.00 -37.13%
on 03/04/26
-34.67 (-26.75%)
since 02/05/26
52-Week
91.01 +4.31%
on 05/06/25
156.00 -39.15%
on 12/02/25
+2.72 (+2.95%)
since 05/05/25

Most Recent Stories

More News
TransMedics: Q1 Earnings Snapshot

TransMedics: Q1 Earnings Snapshot

TMDX : 94.93 (-2.21%)
TransMedics Reports First Quarter 2026 Financial Results

ANDOVER, Mass. , May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage...

TMDX : 94.93 (-2.21%)
TransMedics Reports Tomorrow With Its Expansion Promises Still Ahead of Its Revenue Reality

Barchart Research What to Expect from TMDX Earnings TMDX Generated May 4, 2026 Current Price $97.08 EPS Estimate $$0.62 Consensus Rating Moderate Buy Average Move 12.83% TransMedics Reports Tomorrow With...

TMDX : 94.93 (-2.21%)
TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

Proposed strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, intended to lay the foundation for TransMedics to establish a dedicated organ transplantation...

TMDX : 94.93 (-2.21%)
TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting

Unveils New Controlled Hypothermic Organ Preservation System (CHOPS) to Expand its Product Portfolio and to Facilitate Enrollment in Control Arms of OCS ENHANCE Heart Part B and OCS DENOVO Lung Clinical...

TMDX : 94.93 (-2.21%)
TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026

ANDOVER, Mass. , April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 94.93 (-2.21%)
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results

ANDOVER, Mass. , Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 94.93 (-2.21%)
TransMedics: Q4 Earnings Snapshot

TransMedics: Q4 Earnings Snapshot

TMDX : 94.93 (-2.21%)
TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results

ANDOVER, Mass. , Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 94.93 (-2.21%)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass. , Feb. 20, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 94.93 (-2.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation....

See More

Key Turning Points

3rd Resistance Point 101.06
2nd Resistance Point 99.70
1st Resistance Point 97.32
Last Price 94.93
1st Support Level 93.58
2nd Support Level 92.22
3rd Support Level 89.84

See More

52-Week High 156.00
Fibonacci 61.8% 131.17
Fibonacci 50% 123.51
Fibonacci 38.2% 115.84
Last Price 94.93
52-Week Low 91.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.